Results 11 to 20 of about 1,396,646 (189)
Automating drug discovery [PDF]
Nature Reviews Drug Discovery, 2017 Small-molecule drug discovery can be viewed as a challenging multidimensional problem in which various characteristics of compounds - including efficacy, pharmacokinetics and safety - need to be optimized in parallel to provide drug candidates. Recent advances in areas such as microfluidics-assisted chemical synthesis and biological testing, as well as
Gisbert Schneider
exaly +3 more sources
Antibiotic drug discovery [PDF]
Microbial Biotechnology, 2016 Summary Due to the threat posed by the increase of highly resistant pathogenic bacteria, there is an urgent need for new antibiotics; all the more so since in the last 20 years, the approval for new antibacterial agents had decreased. The field of natural product discovery has undergone a tremendous development over the past few years.
Wohlleben, Wolfgang +3 more
openaire +2 more sources
Computational drug discovery [PDF]
Acta Pharmacologica Sinica, 2012 Computational drug discovery is an effective strategy for accelerating and economizing drug discovery and development process. Because of the dramatic increase in the availability of biological macromolecule and small molecule information, the applicability of computational drug discovery has been extended and broadly applied to nearly every stage in ...
Si-Sheng, Ou-Yang +5 more
openaire +2 more sources
RSC Medicinal Chemistry, 2020 Innovations in mycobacterial drug discovery to accelerate the identification of new drug candidates with confirmed targets and whole cell activity.
Katherine A. Abrahams, Gurdyal S. Besra
openaire +3 more sources
Anticancer Drug Discovery [PDF]
JNCI Journal of the National Cancer Institute, 1991 The National Cancer Institute's (NCI's) human tumor cell line panel for screening potential new anticancer drugs is now operational (/). Its implementation and the demonstration of its feasibility represent a technical and organizational tour de force.
openaire +2 more sources
Fibronectin extra domain A as a drug delivery targeting epitope for rheumatoid arthritis
Advances in Rheumatology, 2022 Objectives To assess the ability of monoclonal antibodies (mAbs) specific for fibronectin extra-domain A (FnEDA) to target diseased tissues of mouse collagen induced arthritis (mCIA) models.
Victor Z. Sun +13 more
doaj +1 more source
Personalized medicine : the impact on chemistry [PDF]
, 2010 An effective strategy for personalized medicine requires a major conceptual change in the development and application of therapeutics. In this article, we argue that further advances in this field should be made with reference to another conceptual shift,
Marsh, Andrew +3 more
core +1 more source
Journal of Translational Medicine, 2016 Background Angiopoietin-2 (Ang-2), a ligand of the Tie-2 receptor, plays an important role in maintaining endothelial cells and in destabilizing blood vessels. Collateral artery growth (arteriogenesis) is a key adaptive response to arterial occlusion. It
Xiaoyong Tan +11 more
doaj +1 more source
Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. [PDF]
, 2020 Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery.
Chandy, Mark +2 more
core
Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB. [PDF]
, 2016 Repurposing has gained momentum globally and become an alternative avenue for drug discovery because of its better success rate, and reduced cost, time and issues related to safety than the conventional drug discovery process.
Brindha, Sridharan +4 more
core +1 more source